Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib

Leukemia Research

Volumn 32, Issue 10, 2008, Pages 1626-1628

  Breccia, M ^a   Muscaritoli, M ^a   Cannella, L ^a   Stefanizzi, C ^a   Frustaci, A ^a   Alimena, G ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; DASATINIB; GLUCOSE; HEMOGLOBIN A1C; HYDROXYUREA; IMATINIB; INSULIN; MERCAPTOPURINE; NILOTINIB;

AGED; CASE REPORT; CHRONIC MYELOID LEUKEMIA; DISEASE COURSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; LETTER; LEUKOCYTOSIS; MUTATION; NEUTROPENIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT RESPONSE; WEIGHT GAIN;

AGED; ANTINEOPLASTIC AGENTS; BLOOD GLUCOSE; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; THIAZOLES; TREATMENT FAILURE;

EID: 44749094403     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.01.015     Document Type: Letter

References (7)

1. Talpaz M., Shah N.P., Kantarjian H., Donato N., Nicoll J., Paquette R., et al. Dasatinib in imatinib resistant Philadelphia chromosome positive leukemias. N Engl J Med 354 (2006) 2531-2541
2. Boren J., Cascante M., Marin S., et al. Gleevec (STI571) influences metabolic enzyme activities and glucose carbon flow toward nucleic acid and fatty acid synthesis in myeloid tumor cells. J Biol Chem 276 (2001) 37747-37753
3. Barnes K., McIntosh E., Whetton A.D., et al. Chronic myeloid leukaemia: an investigation into the role of Bcr-Abl-induced abnormalities in glucose transport regulation. Oncogene 24 (2005) 3257-3267
4. Breccia M., Muscaritoli M., Aversa Z., Mandelli F., and Alimena G. Imatinib mesylate may improve fasting blood glucose in diabetic Ph+ chronic myelogenous leukemia patients responsive to treatment. J Clin Oncol 22 (2005) 4653-4655
5. Hagerkvist R., Sandler S., Mokhtari D., and Welsh N. Amelioration of diabetes by imatinib mesylate (Gleevec): role of beta-cell NF-kappaB activation and anti-apoptotic preconditioning. FASEB J 21 (2007) 618-628
6. Breccia M., Muscaritoli M., Gentilini F., Latagliata R., Carmosino I., Rossi Fanelli F., et al. Impaired fasting glucose level as metabolic side effect of nilotinib in non-diabetic chronic myeloid leukemia patients resistant to imatinib. Leuk Res 31 (2007) 1770-1772
7. 2+-dependent insulin release. Am J Physiol Endocrinol Metab 292 (2007) 845-852